A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
The aim of this study was to seek a better treatment for patients with inoperable or recurrent stomach cancer. Seventy patients were randomly allocated to receive courses of treatment with either A (5-Fluorouracil plus radiotherapy) or B (5-Fluorouracil plus Imidazole Carboxamide Dimethyl Triazeno plus Vincristine plus Bis-Chloroethyl Nitrosourea plus radiotherapy). Only 59 of these patients were evaluable. The median survival time of patients allocated to Group A was 220 days and Group B was 199 days. Seventeen of 31 patients in Group A and 10 of 28 patients in Group B had objectively documented remission. The median survival time of responders was 222 days for Group A and 410 for Group B. While it would appear that those patients who respond to the more intensive treatment do better, a larger percentage of patients responded to the simpler treatment regimen of 5-Fluorouracil plus radiotherapy.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003606:Dacarbazine; D005472:Fluorouracil; D002330:Carmustine